Which two agents are classified as recombinant tissue-type plasminogen activators (tPAs)?

Recombinant tissue-type plasminogen activators (tPAs) are synthetic forms of the natural protein that initiates the breakdown of blood clots. Among the options listed, both Reteplase and Tenecteplase are designed to enhance thrombolytic activity in a clinical setting.

Reteplase is a modified form of tPA that has a longer half-life than the native protein, allowing for a more convenient dosing schedule in acute thrombotic events. It works by converting plasminogen to plasmin, thus facilitating the dissolution of fibrin clots.

Tenecteplase is another engineered tPA that has specific mutations to improve its pharmacokinetic profile. It is also used in the treatment of acute myocardial infarction and offers advantages such as a single bolus administration and greater resistance to plasminogen inhibitors.

Both of these agents are indicated for use in conditions requiring rapid clot dissolution, and their classification as recombinant tissue-type plasminogen activators highlights their role in thrombolytic therapy.